Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know
Genelux Corporation (GNLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
Genelux Corporation (GNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point
Topline results from phase 3 OnPrime/GOG-3076 study using Olvi-Vec for the treatment of patients with platinum-resistant recurrent ovarian cancer, are expected in the 2nd half of 2025. Interim data from phase 2 U.S. trial using Olvi-Vec for the treatment of patients with non-small cell lung cancer is expected mid-2025. Interim results from phase 1b/2 China study, using Olvi-Vec for the treatment of patients with small-cell lung cancer, are expected 2nd half of 2024.
